Another Switch Study

Switching virologically suppressed patients from twice-daily lopinavir/ritonavir to once-daily ritonavir-boosted atazanavir did not result in excessive failure rates but was associated with potentially visible bilirubin elevations.

Lopinavir/ritonavir is a potent boosted PI that has been associated with more adverse metabolic events than some of the newer boosted PIs. Given its favorable lipid profile, boosted atazanavir has been proposed as an effective once-daily alternative.

To evaluate the safety and efficacy of switching from twice-daily lopinavir/r to once-daily ritonavir-boosted atazanavir, investigators conducted a randomized, open-label, noninferiority trial among 248 patients in Spain who had achieved virologic suppression (<200 copies/mL for >6 months) on twice-daily lopinavir/r plus two NRTIs. Per study protocol, none of the patients had more than four PI-associated mutations, and none had experienced more than two instances of virologic failure on PI-conta…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Another Switch Study

Topics

Reviewing Author